Facebook Linkedin RSS Twitter Youtube
Home 2024

Sickle cell disease

StockWatch: ARK Mostly Bullish on CRISPR Therapeutics
GEN Edge

StockWatch: ARK Mostly Bullish on CRISPR Therapeutics

Going Public: Doudna’s Dream Team Launches Groundbreaking Sickle Cell Trial
GEN Edge

Going Public: Doudna’s Dream Team Launches Groundbreaking Sickle Cell Trial

Prime Medicine Spat with Tessera Rumbles on at ESGCT
Genome Editing

Prime Medicine Spat with Tessera Rumbles on at ESGCT

Diverse Genomes Make Medicine More Equitable
Drug Discovery

Diverse Genomes Make Medicine More Equitable

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies
GEN Edge

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies

Standardized Cell and Gene Therapy Hub A Call to Action
Bioprocessing

Standardized Cell and Gene Therapy Hub A Call to Action

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing
Genome Editing

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies
Genome Editing

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies

2025 Cell & Gene Therapy Reimbursement Outlook
Bioprocessing

2025 Cell & Gene Therapy Reimbursement Outlook

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools
GEN Edge

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools

123...12Page 1 of 12
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.